Figure 2. B16-F10 melanoma isolated CD206⁺ TAM are efficient in cross-presentation of soluble OVA Ag.

(A) Timeline of the murine syngeneic tumor model studies, indicating inoculation of B16-F10 melanoma cells (day 0) and respective endpoints (day 21, rapid-growth tumors; day 24, delayed-growth tumors). (B) In vivo B16-F10 tumor growth curves by 2 groups identified as rapid-growth tumor (cyanine blue) and delayed-growth tumor (purple). (C) Bar diagram represents percentage of CD11b⁺F4/80^dim (gray) and CD11b⁺F4/80^hi (red) TAM analyzed in rapid- and delayed-growth tumors by flow cytometry. (D and E) Bar diagrams represent percentage (D) and mean fluorescence intensity (MFI) (E) of CD206⁺ cells from CD11b⁺F4/80^dim (gray) and CD11b⁺F4/80^hi (red) TAM analyzed in rapid- and delayed-growth tumors by flow cytometry. (F) Bar diagram represents percentage of CD8a⁺ T cells in indicated cell division peak upon coculture with TAM (CD11b⁺F4/80⁺) isolated from rapid-growth tumors (cyanine blue) or delayed-growth tumors (purple). (B–F) Data show mean ± SEM (n= 4 mice per group). Unpaired Student’s t test was used. For multiple comparisons Holm-Šídák test was performed (C–E). *P < 0.05, **P < 0.01, ***P < 0.001. Red asterisk indicate the statistical analysis of CD11b⁺F4/80^hi cells between rapid and delayed tumor growth. Black asterisks indicate the statistical analysis of CD11b⁺F4/80^dim cells between rapid and delayed tumor growth.